Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 4451-4460 Newer>

The Motley Fool December 27, 2007 Brian Orelli	Drugmaker Growth: The China Connection Just like other industries, the pharmaceutical industry has realized that China is a good place to find cheap labor. While reluctant to set up FDA-regulated manufacturing plants in China, other stages of drug development can be done there.
The Motley Fool December 27, 2007 Brian Lawler	Breaking Down a Biotech's Assets Enzon Pharmaceuticals becomes the latest drugmaker to receive interest from a hedge fund.
The Motley Fool December 27, 2007 Brian Lawler	A New Era at Millennium? Millennium Pharmaceuticals submits a supplemental New Drug Application with the FDA to expand the use of lead drug Velcade to patients with multiple myeloma.
The Motley Fool December 26, 2007 Brian Lawler	Exelixis Awaits Bristol-Myers Decision Even if Bristol-Myers Squibb decides to discontinue their partnership, it might not mean the end of the road for Exelixis' cancer treatment.
The Motley Fool December 26, 2007 Brian Orelli	Inflamed Anti-Inflammatory Contract Revised J&J and Schering revise their agreement over anti-TNF compounds.
The Motley Fool December 26, 2007 Brian Orelli	Teva's Heartburning Battle Teva launches its generic version of Wyeth's and Altana's heartburn medication, Protonix; those companies attempt to get a preliminary injunction. There are high stakes on both sides of the dispute.
The Motley Fool December 24, 2007 Brian Orelli	Genentech Bails on Altus Biotech giant Genentech pulls out of its partnership with Altus Pharmaceuticals to develop ALTU-238, a crystallized form of human growth hormone, causing Altus' stock to tumble 44%.
The Motley Fool December 24, 2007 Brian Orelli	Catching Up With Par Pharmaceutical The maker of generics finally releases its third-quarter results. Investors, take note.
The Motley Fool December 21, 2007 Brian Lawler	Flamel Wheeling and Dealing Flamel announces very few details about it's latest deal, this time with German drugmaker Merck KGaA.
The Motley Fool December 20, 2007 Brian Orelli	2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something.
<Older 4451-4460 Newer> Return to current articles.